| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (NCT03682289) | Rahul Aggarwal | 2019-01-17 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma (NCT03229278) | Rutgers, The State University of New Jersey | 2017-10-03 |
| sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer (NCT02767921) | University of Southern California | 2016-08-02 |
| Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs (NCT03630692) | Institut Cancerologie de l'Ouest | 2016-03-25 |
| Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations (NCT02646319) | Mayo Clinic | 2016-01-01 |
| Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer (NCT02664883) | University of Southern California | 2015-09-08 |
| 18F-FSPG PET/CT for Cancer Patients on Therapy (NCT02599194) | Andrei Iagaru | 2015-07-01 |
| Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors (NCT02526511) | Rutgers, The State University of New Jersey | 2015-04-01 |
| Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer (NCT02318771) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-02-05 |
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery (NCT02166255) | Wake Forest University Health Sciences | 2014-12-01 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer (NCT02273752) | Emory University | 2014-11-01 |
| Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers (NCT01846520) | City of Hope Medical Center | 2013-10-01 |
| Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer (NCT01727076) | National Cancer Institute (NCI) | 2013-02-15 |
| Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery (NCT01688973) | National Cancer Institute (NCI) | 2012-08-20 |
| Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT01548482) | National Cancer Institute (NCI) | 2012-03-01 |
| Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies (NCT01243359) | National Cancer Institute (NCI) | 2010-10-01 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors (NCT01198184) | National Cancer Institute (NCI) | 2010-08-01 |
| Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer (NCT01158521) | Case Comprehensive Cancer Center | 2010-06-01 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT01155258) | University of Southern California | 2010-06-01 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (NCT01131234) | National Cancer Institute (NCI) | 2010-05-01 |
| Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate (NCT01582009) | Roswell Park Cancer Institute | 2010-03-01 |
| Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery (NCT01061411) | Roswell Park Cancer Institute | 2010-02-06 |
| Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer (NCT01026337) | Abramson Cancer Center at Penn Medicine | 2009-04-01 |
| Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer (NCT00684996) | National Cancer Institute (NCI) | 2008-06-01 |
| Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors (NCT00499135) | National Cancer Institute (NCI) | 2007-05-22 |
| Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors (NCT00335556) | Children's Oncology Group | 2006-06-01 |
| Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer (NCT00354250) | National Cancer Institute (NCI) | 2006-05-01 |
| Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer (NCT00324740) | National Cancer Institute (NCI) | 2006-03-01 |
| Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer (NCT00324870) | National Cancer Institute (NCI) | 2006-02-01 |
| Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer (NCT00182702) | National Cancer Institute (NCI) | 2005-07-01 |
| Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer (NCT00098618) | National Cancer Institute (NCI) | 2004-10-01 |
| Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer (NCT00101114) | National Cancer Institute (NCI) | 2004-09-01 |
| Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer (NCT00060307) | National Cancer Institute (NCI) | 2003-05-01 |
| Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer (NCT00032188) | National Cancer Institute (NCI) | 2002-01-01 |
| Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer (NCT00005799) | Fred Hutchinson Cancer Center | 1999-11-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |